Publications by authors named "M Civallero"
Article Synopsis
- Variations in access to drugs globally make it hard to assess the effectiveness of modern treatments for patients with relapsed and refractory mature T-cell and NK-cell lymphomas in a study of 925 patients.
- * The study found that relapsed lymphoma patients had better overall survival rates compared to refractory patients after second-line treatment, with several factors identified as predictors of survival.
- * A new prognostic index (PIRT) categorizes patients based on risk factors into low, intermediate, or high risk, impacting 3-year overall survival rates, and highlights the superior outcomes of novel therapies compared to traditional chemotherapy.
Introduction: The histological transformation (HT) of follicular lymphoma (FL) is a crucial biological event. The study aimed to evaluate the incidence, clinicial characteristics, prognosis and impact of HT time on survival of FL transforming to diffuse large B-cell lymphoma in population-based large-scale cohorts.
Methods: A retrospective cohort study of FL with HT was performed in the Surveillance, Epidemiology, and End Results database.
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally.
View Article and Find Full Text PDFWe report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019-2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130 (23.1%) of diffuse large B-cell lymphoma (DLBCL), 28 (5%) of follicular lymphoma (FL), 16 (2.
View Article and Find Full Text PDFArticle Synopsis
- The study examined outcomes and prognostic factors in patients with limited-stage peripheral T-cell lymphomas (PTCLs) using data from the T-Cell Project, involving 211 patients from 2006-2018.
- A newly developed model identified risk groups based on factors like age, LDH levels, and serum albumin, showing varying 5-year overall survival rates (OS) of 78%, 46%, and 25% for low, intermediate, and high-risk groups, respectively.
- The SALENTO Model outperformed existing prognostic indices and revealed that high-risk patients have poor outcomes similar to advanced-stage disease, suggesting a need for more aggressive first-line treatments.